Merck KGaA says it can catch up in immuno-oncology with Pfizer's help

Merck KGaA, long plagued by clinical setbacks, is pushing into Phase III with a Pfizer ($PFE)-partnered cancer treatment, believing it can eventually catch up with rivals already on the market. The German company kicked off a late-stage lung cancer trial on avelumab, an antibody that blocks PD-L1 to activate immune cells, and healthcare chief Belen Garijo told Reuters the drugmaker has a plan to contend with Merck ($MRK), Bristol-Myers Squibb ($BMY) and others by pursuing trials in underserved cancer types. Pfizer bought into avelumab in a sweeping collaboration deal last year. More

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.